TY - JOUR T1 - High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01154-2020 SP - 2001154 AU - Tiphaine Guy AU - Audrey Créac'hcadec AU - Charles Ricordel AU - Alexandre Salé AU - Baptiste Arnouat AU - Jean-Louis Bizec AU - Marie Langelot AU - Christine Lineau AU - David Marquette AU - Françoise Martin AU - Mathieu Lederlin AU - Stéphane Jouneau Y1 - 2020/01/01 UR - http://erj.ersjournals.com/content/early/2020/08/03/13993003.01154-2020.abstract N2 - The new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease (COVID-19), now recognised by the WHO as a pandemic, emerged in late 2019 in China [1]. Patients infected with SARS-CoV-2 can develop severe pneumonia and respiratory failure, which often require treatment in intensive care units (ICU) in Western European countries [2]. Oxygen therapy and supportive care are still the main forms of therapy for SARS-CoV-2 pneumonia until suitable anti-infective therapies become available.SARS-CoV2 infected patients with non-hypercapnic acute hypoxemic respiratory failure can benefit from HFNO outside an ICU. The technique appears to be safe for HCWs and could well liberate critical ICU resources. ER -